Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18617912 | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | March 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18391867 | RE-AGGREGATION OF STEM CELL-DERIVED PANCREATIC BETA CELLS | December 2023 | January 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18454288 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | August 2023 | August 2024 | Allow | 11 | 0 | 0 | No | No |
| 18347009 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED COAGULATION FACTOR 12 LOCUS | July 2023 | September 2024 | Allow | 14 | 0 | 0 | No | No |
| 18003067 | THREE-DIMENSIONAL BIOMIMETIC CHIP FOR SIMULATING ENDOMETRIUM, AND ENDOMETRIUM SIMULATING METHOD USING SAME | December 2022 | February 2025 | Allow | 26 | 2 | 0 | No | No |
| 17746664 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR | May 2022 | December 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17703927 | EFFICIENT TCR GENE EDITING IN T LYMPHOCYTES | March 2022 | August 2024 | Allow | 28 | 1 | 1 | No | No |
| 17554881 | APPLICATION OF A FRAGMENT OF AN ISOLATED NUCLEOTIDE SEQUENCE IN CONSTRUCTION OF NON-MINERALIZED INTERMUSCULAR BONE OF DANIO RERIO | December 2021 | February 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17535071 | CELLULAR THERAPEUTICS ENGINEERED WITH SIGNAL MODULATORS AND METHODS OF USE THEREOF | November 2021 | April 2025 | Abandon | 41 | 2 | 1 | No | Yes |
| 17534341 | METHODS FOR MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING REJUVENATED T CELLS | November 2021 | May 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17508446 | MODIFIED T CELLS, PHARMACEUTICAL COMPOSITION, MANUFACTURING METHOD THEREOF, AND METHOD OF USING THE SAME | October 2021 | April 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17504752 | Mouse Model of Alcohol-induced Liver Cancer | October 2021 | October 2024 | Allow | 36 | 3 | 1 | Yes | No |
| 17602929 | METHOD FOR PRODUCING NK CELLS WITH PD-1 KNOCKOUT GENE AND TRAIL OR FAS-LIGAND OVEREXPRESSION | October 2021 | April 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17497409 | METHOD FOR CULTIVATING PRIMARY HUMAN PULMONARY ALVEOLAR EPITHELIAL CELLS AND APPLICATION THEREOF | October 2021 | August 2023 | Allow | 22 | 2 | 0 | Yes | No |
| 17484324 | METHODS OF TREATING MITOCHONDRIAL DISORDERS | September 2021 | March 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17593066 | HUMANIZED ANTI-CLAUDIN 18.2 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | September 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17434814 | ACTIVATED LYMPHOCYTES COMPRISING CYTOKINE-INDUCED KILLER CELLS AND PREPARATION METHOD THEREFOR | August 2021 | February 2025 | Allow | 41 | 1 | 1 | No | No |
| 17409504 | METHODS FOR ISOLATING CD8+ SELECTED T CELLS | August 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17429007 | BIOMATERIALS AND METHODS RELATED THERETO | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17443590 | DECELLULARIZED FETAL MATRIX FOR TISSUE REGENERATION | July 2021 | May 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17351343 | TTF Generated Proliferation of Cytotoxic T Cells to Create a Specific Pro-Inflammatory Response | June 2021 | December 2023 | Abandon | 30 | 2 | 0 | No | No |
| 17349328 | MATERIALS AND METHODS FOR THE MANUFACTURE OF PLURIPOTENT STEM CELLS | June 2021 | January 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17333005 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | May 2021 | January 2025 | Allow | 44 | 3 | 0 | Yes | No |
| 17296859 | T-Rapa Cells as Novel Effector Cell Type for Chimeric Antigen Receptor Therapy | May 2021 | April 2024 | Allow | 35 | 2 | 0 | No | No |
| 17320663 | Immunosuppressive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune and Alloimmune Disorders | May 2021 | July 2023 | Allow | 26 | 1 | 1 | No | No |
| 17291853 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS | May 2021 | September 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17239289 | RUNX3 MODIFIED PROTEIN FOR PREVENTION OR TREATMENT OF CANCER | April 2021 | November 2023 | Allow | 31 | 2 | 0 | No | No |
| 17231963 | PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF DYNAMIN-1 VARIANTS | April 2021 | December 2024 | Allow | 44 | 3 | 0 | Yes | No |
| 17224924 | METHODS FOR THE LONG-TERM EXPANSION OF GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | April 2021 | February 2024 | Allow | 35 | 1 | 0 | No | No |
| 17221625 | ENHANCEMENT OF ADOPTIVE CELL TRANSFER | April 2021 | September 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17205700 | METHOD FOR THE CULTURING OF CELLS | March 2021 | July 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17184231 | COMPOSITIONS AND MATERIALS FOR REGENERATION OF SKELETAL MUSCLE | February 2021 | August 2024 | Allow | 42 | 4 | 1 | Yes | No |
| 17180754 | CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | February 2021 | November 2024 | Allow | 44 | 5 | 0 | Yes | No |
| 17176907 | PLATELET-DERIVED MITOCHONDRIA TREATMENT AND METHOD OF GENERATING MULTIPOTENT CELLS | February 2021 | May 2024 | Allow | 39 | 3 | 0 | No | No |
| 17265157 | COMPOSITIONS AND METHODS FOR IMPROVING EMBRYO DEVELOPMENT | February 2021 | November 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 17265048 | CAR T-CELLS FOR THE TREATMENT OF BONE METASTATIC CANCER | February 2021 | August 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17163316 | PLACENTAL DERIVED NATURAL KILLER CELLS FOR TREATMENT OF CORONAVIRUS INFECTIONS | January 2021 | September 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17160694 | COMPOSITION FOR INHIBITING EXTENSION OF POPULATION DOUBLING TIME OF STEM CELLS, COMPRISING C-MET AGONIST ANTIBODY AS ACTIVE INGREDIENT | January 2021 | May 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17158705 | METHODS AND DEVICES FOR THE GENERATION OF OOCYTES WITH IMPROVED OOCYTE QUALITY FOR IN VITRO FERTILIZATION PROCEDURES USING NON-INVASIVE CELLULAR TRANSFER | January 2021 | August 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17259900 | NON-IMMUNOGENIC ENGINEERED TISSUE AND METHODS OF PRODUCING AND USING THE SAME | January 2021 | March 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17258716 | MICROFLUIDIC METHODS FOR THE PREPARATION OF CELLS | January 2021 | June 2025 | Abandon | 53 | 2 | 0 | No | No |
| 17255005 | ANTI-SLAMF7 CHIMERIC ANTIGEN RECEPTORS | December 2020 | December 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 17253536 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA TO A CELL | December 2020 | August 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17253159 | STEM CELL BIOMIMETIC NANOPARTICLE THERAPEUTIC AGENTS AND USES THEREOF | December 2020 | July 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16972655 | ANTISENSE OLIGONUCLEOTIDES TO RESTORE DYSFERLIN PROTEIN EXPRESSION IN DYSFERLINOPATHY PATIENT CELLS | December 2020 | July 2024 | Allow | 44 | 1 | 1 | No | No |
| 17113068 | RECRUITMENT METHODS AND COMPOUNDS, COMPOSITIONS AND SYSTEMS FOR RECRUITMENT | December 2020 | January 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 15734210 | STEM CELL FILTRATE PREPARATION AND METHOD FOR PREPARING SAME | December 2020 | May 2024 | Allow | 41 | 2 | 0 | No | No |
| 17104961 | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | November 2020 | December 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 17097458 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | November 2020 | February 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17096322 | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | November 2020 | November 2023 | Abandon | 36 | 2 | 1 | Yes | No |
| 17093943 | QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING | November 2020 | July 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 17092906 | COMBINATION OF ANTISENSE RNA SEQUENCES AND USE IN THE PRODUCTION OF TILAPIA WITH DEGENERATED SEXUAL ORGANS | November 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17080336 | INJECTABLE, BIOADHESIVE CRYOGEL SCAFFOLDS FOR BIOMEDICAL USES | October 2020 | August 2023 | Allow | 33 | 2 | 1 | No | No |
| 17050354 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | October 2020 | February 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17079097 | MODIFIED DOUBLE-STRANDED DONOR TEMPLATES | October 2020 | April 2024 | Allow | 42 | 3 | 1 | Yes | No |
| 17077762 | GRNA TARGETING MIR-29B, AAV8-CRISPR/CAS9 SYSTEM AND USE THEREOF | October 2020 | June 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17048239 | METHOD FOR ENHANCING THE SUPPRESSIVE PROPERTIES OF TREG CELLS | October 2020 | April 2024 | Allow | 42 | 1 | 0 | No | No |
| 17061978 | CRNN LOSS OF FUNCTION RODENT MODEL | October 2020 | July 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17035955 | ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL | September 2020 | January 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17040953 | TECHNIQUES FOR PROMOTING NEURONAL RECOVERY | September 2020 | March 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17040865 | METHOD FOR PROMOTING PROLIFERATION OF IMMUNE CELLS | September 2020 | January 2024 | Allow | 40 | 2 | 1 | Yes | Yes |
| 17040421 | ENDOTHELIAL CELL FACTORS AND METHODS THEREOF | September 2020 | June 2024 | Allow | 44 | 2 | 1 | No | No |
| 16981086 | Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism | September 2020 | March 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 16944730 | METHOD FOR PRODUCING CELL | July 2020 | December 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16966406 | ORGANOIDS RELATED TO IMMUNOTHERAPY AND METHODS OF PREPARING AND USING THE SAME | July 2020 | April 2024 | Allow | 45 | 1 | 1 | No | No |
| 16965197 | NEUTROPHIL SUBTYPES | July 2020 | April 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16962672 | GENERATION, PROLIFERATION AND EXPANSION OF EPITHELIAL CELLS FROM PRIMARY TISSUE INTO MUCOSOID CULTURES | July 2020 | March 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 16962294 | METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY IN COMBINATION WITH 4-1BB AGONIST | July 2020 | June 2024 | Abandon | 47 | 2 | 0 | Yes | Yes |
| 16961314 | COMPOSITIONS AND METHODS FOR GENE EDITING BY TARGETING TRANSFERRIN | July 2020 | September 2024 | Allow | 50 | 2 | 1 | No | No |
| 16915243 | TROPISM MODIFIED CANCER TERMINATOR VIRUS (AD.5/3 CTV;AD.5/3-CTV-M7) | June 2020 | July 2024 | Abandon | 49 | 2 | 0 | No | Yes |
| 16898844 | MEDIUM FOR CULTURING STEM CELLS | June 2020 | September 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16768807 | PROTEIN-FREE SEMEN CRYOPRESERVATION | June 2020 | June 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16838519 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED COAGULATION FACTOR 12 LOCUS | April 2020 | April 2023 | Allow | 36 | 2 | 0 | Yes | No |
| 16648567 | GENE EDITING T CELL AND USE THEREOF | March 2020 | March 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16820368 | METHODS OF TREATING MITOCHONDRIAL DISORDERS | March 2020 | April 2024 | Allow | 49 | 2 | 0 | Yes | No |
| 16615009 | METHOD FOR ESTABLISHING AN ORAL ULCER ANIMAL MODEL WITH YIN-DEFICIENCY AND FIRE-EXCESS SYNDROME BASED ON SLEEP DEPRIVATION | March 2020 | March 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16719417 | SYSTEM AND A METHOD FOR PRODUCING AN ENCAPSULATED CELLULAR SPHEROID | December 2019 | August 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16593840 | NOVEL MICRO-DYSTROPHINS AND RELATED METHODS OF USE | October 2019 | May 2025 | Allow | 60 | 3 | 0 | Yes | No |
| 16493716 | LABELING, ISOLATION, & ANALYSIS OF RNA FROM RARE CELL POPULATIONS | September 2019 | January 2024 | Abandon | 52 | 2 | 0 | No | No |
| 16553728 | APPARATUS AND METHOD TO ISOLATE SPERM BASED ON PLANAR-CONFINED SWIMMING | August 2019 | March 2023 | Abandon | 42 | 1 | 0 | No | No |
| 16444174 | ANIMAL MODEL OF NON-ALCOHOLIC LIVER DISEASE AND COMPOSITION OF DIAGNOSIS, PREVENTION OR TREATMENT FOR NON-ALCOHOLIC LIVER DISEASE | June 2019 | March 2023 | Allow | 45 | 1 | 1 | Yes | No |
| 16465933 | ARTIFICIAL ANTIGEN-PRESENTING CELL PREPARED FROM HLA-NULL CELL LINE BY USING MULTIPLEX CRISPR-CAS9 SYSTEM AND USE THEREOF | May 2019 | August 2023 | Allow | 50 | 3 | 0 | No | No |
| 16347716 | AN ENGINEERED TWO-PART CELLULAR DEVICE FOR DISCOVERY AND CHARACTERISATION OF T-CELL RECEPTOR INTERACTION WITH COGNATE ANTIGEN | May 2019 | August 2023 | Abandon | 52 | 1 | 1 | Yes | No |
| 16082487 | METHODS OF TREATING MITOCHONDRIAL DISORDERS | September 2018 | March 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 15579802 | MECHANICAL APPARATUS AND METHOD FOR ISOLATING STROMAL VASCULAR FRACTION | December 2017 | September 2023 | Allow | 60 | 6 | 1 | Yes | No |
| 15573266 | BLOOD CULTURE SYSTEM WITH LOW MEDIA VOLUME | November 2017 | August 2023 | Allow | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WESTON, ALYSSA G.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WESTON, ALYSSA G works in Art Unit 1633 and has examined 85 patent applications in our dataset. With an allowance rate of 67.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner WESTON, ALYSSA G's allowance rate of 67.1% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WESTON, ALYSSA G receive 1.82 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WESTON, ALYSSA G is 41 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +51.0% benefit to allowance rate for applications examined by WESTON, ALYSSA G. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 36.2% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 27.6% of cases where such amendments are filed. This entry rate is in the 30% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 84.8% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.0% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.